Literature DB >> 14989601

Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa).

John K Cowell1, Gene H Barnett, Norma J Nowak.   

Abstract

Loss of genetic material from the short arm of chromosome 1 and the long arm of chromosome 19 in anaplastic oligodendrogliomas has been shown to predict responsiveness to chemotherapy. Currently, the most common approach used to detect this loss of 1p/19q material employs microsatellite/FISH analysis using markers along the length of these chromosome arms. This analysis is highly focused and carried out on a locus-by-locus basis and gives no indication of the extent of other genetic changes occurring in the tumor cells, which may be important in future studies to explore genetic heterogeneity in the response to treatment. We have investigated the use of comparative genomic hybridization arrays (CGHa) of bacterial artificial chromosomes (BACs) in the identification of tumor samples that carry loss of the 1p/19q chromosome arms. These BAC arrays carry approximately 6,000 BAC clones and provide an average inter-BAC resolution of 500 Kb. Using this approach we have clearly shown that 1p/19q loss in these cases, when compared with microsatellite-mediated detection of loss of heterozygosity, is due to physical hemizygous deletion of the whole chromosome arms in all cases. Furthermore, CGHa allows the simultaneous definition of the other genetic changes that are occurring in the tumors. From our survey of 14 tumors consisting of low-grade oligodendrogliomas (n = 6), anaplastic oligodendrogliomas (n = 5), or mixed oligoastrocytoma (n = 3). we were able to demonstrate the presence of additional genetic markers that were characteristic of the various grades of tumors as well as novel changes that had occurred. Thus, CGHa provides a robust, high throughput, genome-wide analysis of genetic changes of oligodendroglial tumors that can be used not only to predict chemo-responsiveness but also place these genetic changes in the context of other abnormalities in the same experiment without the need for extensive chromosome or LOH analysis.

Entities:  

Mesh:

Year:  2004        PMID: 14989601     DOI: 10.1093/jnen/63.2.151

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  16 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors.

Authors:  Haihui Jiang; Zhe Zhang; Xiaohui Ren; Wei Zeng; Wenqing Jia; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

3.  Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors.

Authors:  Judith Jeuken; Sandra Cornelissen; Sandra Boots-Sprenger; Sabine Gijsen; Pieter Wesseling
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Authors:  David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke
Journal:  Converg Sci Phys Oncol       Date:  2015-06-16

5.  Defined genetic events associated with the spontaneous in vitro transformation of ElA/Ras-expressing human IMR90 fibroblasts.

Authors:  Douglas X Mason; Daniel Keppler; Jun Zhang; Tonya J Jackson; Yvette R Seger; Seiichi Matsui; Fleurette Abreo; John K Cowell; Gregory J Hannon; Scott W Lowe; Athena W Lin
Journal:  Carcinogenesis       Date:  2005-11-09       Impact factor: 4.944

6.  The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jonathan Hobbs; Stephanie Bortoluzzi; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

7.  Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.

Authors:  Ahmed Idbaih; Cyril Dalmasso; Mathilde Kouwenhoven; Judith Jeuken; Catherine Carpentier; Thierry Gorlia; Johan M Kros; Pim French; Johannes Teepen; Philippe Broët; Olivier Delattre; Karima Mokhtari; Marc Sanson; Jean-Yves Delattre; Martin van den Bent; Khê Hoang-Xuan
Journal:  J Neurooncol       Date:  2010-09-06       Impact factor: 4.130

8.  Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Authors:  Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Audrey Rousseau; Karima Mokhtari; Michèle Kujas; Younas El Houfi; Catherine Carpentier; Sophie Paris; Blandine Boisselier; Florence Laigle-Donadey; Joëlle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Neuro Oncol       Date:  2008-06-10       Impact factor: 12.300

9.  Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.

Authors:  Jongmin Sim; Do-Hyun Nam; Yuil Kim; In-Hee Lee; Jung Won Choi; Jason K Sa; Yeon-Lim Suh
Journal:  Med Oncol       Date:  2018-03-29       Impact factor: 3.064

10.  Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19.

Authors:  Kristen L Drucker; Gaspar J Kitange; Thomas M Kollmeyer; Mark E Law; Sandra Passe; Amanda L Rynearson; Hilary Blair; Cheryl L Soderberg; Bruce W Morlan; Karla V Ballman; Caterina Giannini; Robert B Jenkins
Journal:  Genes Chromosomes Cancer       Date:  2009-10       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.